Nuvectis Pharma, Inc. (NVCT)
21.08
+0.06
(+0.29%)
USD |
NASDAQ |
Nov 10, 16:00
21.19
+0.11
(+0.52%)
After-Hours: 20:00
Nuvectis Pharma Enterprise Value : 400.56M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 400.56M |
| November 09, 2026 | 399.02M |
| November 06, 2026 | 396.19M |
| November 05, 2026 | 315.31M |
| November 04, 2026 | 333.54M |
| November 03, 2026 | 355.88M |
| November 02, 2026 | 351.77M |
| October 30, 2026 | 333.80M |
| October 29, 2026 | 336.11M |
| October 28, 2026 | 330.72M |
| October 27, 2026 | 332.77M |
| October 26, 2026 | 334.06M |
| October 23, 2026 | 374.11M |
| October 22, 2026 | 395.68M |
| October 21, 2026 | 390.80M |
| October 20, 2026 | 387.98M |
| October 19, 2026 | 345.61M |
| October 16, 2026 | 336.88M |
| October 15, 2026 | 345.35M |
| October 14, 2026 | 321.48M |
| October 13, 2026 | 325.33M |
| October 12, 2026 | 364.87M |
| October 09, 2026 | 401.59M |
| October 08, 2026 | 376.17M |
| October 07, 2026 | 380.28M |
| Date | Value |
|---|---|
| October 06, 2026 | 373.60M |
| October 05, 2026 | 408.52M |
| October 02, 2026 | 422.13M |
| October 01, 2026 | 391.32M |
| September 30, 2026 | 401.59M |
| September 29, 2026 | 525.88M |
| September 28, 2026 | 533.36M |
| September 25, 2026 | 517.61M |
| September 24, 2026 | 555.25M |
| September 23, 2026 | 540.30M |
| September 22, 2026 | 591.82M |
| September 21, 2026 | 564.59M |
| September 18, 2026 | 565.13M |
| September 17, 2026 | 548.57M |
| September 16, 2026 | 561.66M |
| September 15, 2026 | 562.99M |
| September 14, 2026 | 601.16M |
| September 11, 2026 | 618.25M |
| September 10, 2026 | 578.21M |
| September 09, 2026 | 585.95M |
| September 08, 2026 | 618.25M |
| September 04, 2026 | 631.60M |
| September 03, 2026 | 628.39M |
| September 02, 2026 | 616.38M |
| September 01, 2026 | 593.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Opus Genetics, Inc. | 350.79M |
| Faeth Therapeutics, Inc. | 166.00M |
| ACADIA Pharmaceuticals, Inc. | 2.254B |
| Alnylam Pharmaceuticals, Inc. | 19.71B |
| Anika Therapeutics, Inc. | 161.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.07M |
| Total Expenses (Quarterly) | 30.07M |
| EPS Diluted (Quarterly) | -1.020 |
| Earnings Yield | -8.84% |
| Normalized Earnings Yield | -8.836 |